Joel Ackerman was appointed Chairman of the Board of Directors of the Company in January 2017. He was CEO and Director of the Company from 2010 to 2017. Prior to Champions, he spent 15 years at Warburg Pincus, a leading private equity investment firm, from 1993 to 2008. While at Warburg Pincus, he was a partner of the firm, a member of the executive management group and ran the healthcare services group. He invested in start-ups and early-stage companies as well as later-stage growth investments and management-led buyouts. For most of these companies, Mr. Ackerman served on the board of directors and worked closely with the respective management teams on strategy, financing, M&A and organizational development. Currently, Mr. Ackerman sits on the board of directors of Coventry Health Care, a publicly traded managed care company, and Kindred Healthcare, a publicly traded company that owns hospitals and nursing homes. He is also chairman of the board of One Acre Fund, a nonprofit microfinance organization in Western Kenya. He received a BA in physics from Columbia University and an MA in physics from Harvard University

Rob Brainin is a Senior Life Sciences/Healthcare Executive based in Boston, MA. He currently served as the EVP, Chief Business Officer at Veracyte, a genomic diagnostics company whose tests provide answers that improve care throughout the patient journey.  He recently served as the Chief Executive Officer at Genuity Science (f/k/a WuXi NextCode), a company focused on integrating clinical and molecular data to derive insights that accelerate drug discovery and development, and ultimately improve healthcare. Prior to that, he served as the Vice President and General Manager of the Life Sciences and Applied Genomics Business at Illumina, a leading global genomics company, and before that as a Vice President/General Manager of the Enterprise Genomics Solutions business of Thermo Fisher Scientific, Inc. He joined Thermo Fisher via its acquisition of Life Technologies, Inc. in 2014. From 2004 to 2014, Mr. Brainin served in a number of positions at Life Technologies and its predecessor, Invitrogen, predominantly leading a variety of large businesses that served customers in the academic and BioPharma segments. Earlier in his career, he was a management consultant at McKinsey & Co. and has served as an adjunct professor at the University of San Diego School of Law.  He is currently on the Board of Directors of the Children’s Tumor Foundation.  He received his Bachelor of Arts degree in Economics, with honors, from Emory University and received his Juris Doctor degree, cum laude, from Harvard Law School.

Philip Breitfeld, MD, serves as the Chief Strategy & Innovation Officer at Champions Oncology.  Dr. Breitfeld has more than 30 years of experience in oncology and was most recently Global Vice President at IQVIA, responsible for the Therapeutic Centers of Excellence. Prior to that, he led the Oncology Center of Excellence at IQVIA where he worked with many large, mid-size and emerging biopharmaceutical firms. He held senior clinical development positions at Merck KGaA (EMD Serono in the US), where he led oncology development in the US, and at BioCryst, where he led oncology development and was Associate Chief Medical Officer.

Prior to his career in industry, he held academic positions at Harvard, University of Massachusetts, Indiana University, and Duke. He has approximately 50 publications in the literature dealing with basic cell and molecular biology, and translational and clinical oncology. He was trained in Pediatric Hematology/Oncology at the Dana-Farber Cancer Institute, was a visiting scientist at the Whitehead Institute at MIT, received his medical degree (MD) from the University of Rochester, and his undergraduate degree (AB in chemistry) from Princeton. Dr. Breitfeld is also a Director on the Company’s Board of Directors.

Dan Mendelson has served as a Director of the Company since March 2013.  He is Founder and former CEO of Avalere Health, a vibrant community of innovative thinkers dedicated to solving the challenges of the healthcare system.  He is also Operating Partner at Welsh Carson, a private equity firm focused on healthcare and technology investments.  Prior to founding Avalere in 2000, Dan served as Associate Director for Health at the Office of Management and Budget in the Clinton White House, where he was responsible for the full healthcare portfolio including Medicare, Medicaid, NIH, CDC, and FDA. 

Dan presently also serves on the boards of Centrexion Corporation, Audacious Inquiry, and Partners in Primary Care.  He is Adjunct Professor at Georgetown University’s McDonough School of Business, and a founding member of Guidon Partners, an investment management group.  Dan also serves on the board of the Alliance for Health Policy.  He previously served on the boards of Coventry Healthcare (CVTY, sold to Aetna in 2013), PharMerica (PMC, sold to KKR in 2017) and HMS holdings (HMSY).  He holds a BA from Oberlin College, and an MPP from the Kennedy School at Harvard University.

Ronnie Morris, MD, serves as Champion Oncology Chief Executive Officer and was most recently one of the founders of MDVIP, the national leader in personalized healthcare. Serving as a board member, medical director and part of the executive management team, Dr. Morris helped build and manage MDVIP, a company that grew to a network of 400 doctors within 29 states servicing 125,000 consumers/patients. In December 2009, MDVIP was acquired by the Procter and Gamble Co. Prior to MDVIP, Dr. Morris was the chief medical officer and executive VP of AllianceCare, a 1500-plus-employee company that provided home healthcare, physical therapy and doctor visits for homebound patients.

At AllianceCare, Dr. Morris developed and operated the physician house call division of the business, and he was the general medical director for the company. He was the managing partner of a large multispecialty group that was acquired in 1998 by ProMedCo. Dr. Morris is a board-certified internist and until 2004, he had a private practice in Boca Raton, Florida. He has been a consultant for many pharmaceutical companies, including Pfizer, Merck and AstraZeneca.

David Sidransky, MD was appointed Lead Director of the Company in January 2017. He was Chairman of the Board of Directors of the Company from 2007 to 2017. Dr. Sidransky is a renowned oncologist and research scientist named and profiled by TIME magazine in 2001 as one of the top physicians and scientists in America, recognized for his work with early detection of cancer. Since 1994, Dr. Sidransky has been the director of the Head and Neck Cancer Research Division at Johns Hopkins University School of Medicine and professor of oncology, otolaryngology, cellular & molecular medicine, urology, genetics, and pathology at John Hopkins University and Hospital.

During the past decade, in the field of oncology, Dr. Sidransky has been one of the world’s most highly cited researchers in clinic and medical journals, with over 300 peer-reviewed publications. He has contributed more than 40 cancer reviews and chapters. Dr. Sidransky is a founder of a number of biotechnology companies and holds numerous biotechnology patents. He has served as vice chairman of the board of directors, and was, until the merger with Eli Lilly, a director of ImClone Systems Inc., a global biopharmaceutical company committed to advancing oncology care. He is the chairman of Alfacell Corporation and serves on the board of directors of Xenomics. He is serving, and has served, on scientific advisory boards of MedImmune, Roche, Amgen and Veridex, LLC (a Johnson & Johnson diagnostic company), among others. Dr. Sidransky served as director (2005-2008) of the American Association for Cancer Research (AACR). He was the chairperson of AACR International Conferences (2006 and 2007) on Molecular Diagnostics in Cancer Therapeutic Development: Maximizing Opportunities for Personalized Treatment.

Dr. Sidransky is the recipient of a number of awards and honors, including the 1997 Sarstedt International Prize from the German Society of Clinical Chemistry, the 1998 Alton Ochsner Award Relating Smoking and Health by the American College of Chest Physicians, and the 2004 Richard and Hinda Rosenthal Memorial Award from the American Association for Cancer Research.

Scott R. Tobin has served as Director of the Company since June 2011. Mr. Tobin joined Battery Ventures, a venture capital/private equity firm, in 1997 where he has been a managing partner of various funds affiliated with the firm since May 2000. He leads investments in the United States, Israel and Europe and has focused his investments in enterprise infrastructure, materials science, application software, business services, media and financial services. Mr. Tobin has been named multiple times to the Forbes Midas List, which ranks top venture capitalists from around the world. He graduated with honors from Brandeis University with a BA in International Relations and Islamic and Middle Eastern Studies.